I last wrote about CVRx Inc (NASDAQ: CVRX ) with the thesis that the stock was very expensive and the company's top-line growth was priced in. Since my last article, the stock has fallen a dramatic 60%. Off ofAmateur value investor seeking bargains in any market, with a specific focus on emerging markets. Admires great investors such as Li Lu and Peter Lynch, and am not afraid to go against the grain. Willing to buy any company at the right price, and is looking for low-risk and high uncertainty bets. My pu ...

Financial Results - CVRx, Inc. announced preliminary financial results for Q1 2025, ending March 31, 2025[5] - A press release detailing the financial results was issued on April 7, 2025[5] Company Classification - The company is classified as an emerging growth company under the Securities Act of 1933[4]

First quarter revenue expected to be approximately $12.3 million, representing growth of approximately 15% over first quarter 2024MINNEAPOLIS, April 07, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced certain preliminary unaudited first quarter 2025 revenue results. “While we continue to make significant progress in driving adoption of Barostim, first quarter revenue fell short of our expectations,” said Kevin Hykes, President and Chief ...

(Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the fiscal year ended December 31, 2024 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to or Commission File Number: 001-40545 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 41-1983744 (State or other jurisdiction o ...

Core Insights - New real-world evidence presented at THT 2025 shows significant reductions in hospital visits and length of stay for heart failure patients after Barostim implantation [1][2] - The study highlights the clinical and economic benefits of the Barostim device, emphasizing its importance for clinicians and payers [2] Company Overview - CVRx, Inc. is a commercial-stage medical device company focused on the development and commercialization of the Barostim™ System, which is the first FDA-approved technology using neuromodulation for heart failure [3] - The Barostim device delivers electrical pulses to baroreceptors in the carotid artery, aiming to restore balance to the autonomic nervous system and alleviate heart failure symptoms [3] Study Findings - The analysis utilized data from the Premier Healthcare Database, involving 306 Barostim patients, comparing healthcare utilization before and after implantation [2] - Results indicated an 86% reduction in all-cause hospital visits, an 84% reduction in cardiovascular hospital visits, and an 85% reduction in heart failure-related hospital visits, all with p-values less than 0.0001 [4]

A downtrend has been apparent in CVRx (CVRX) lately. While the stock has lost 10.1% over the past two weeks, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support.While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about the future earnings ...

Shares of CVRx (CVRX) have gained 3.8% over the past four weeks to close the last trading session at $14.71, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $18.50 indicates a potential upside of 25.8%.The mean estimate comprises six short-term price targets with a standard deviation of $3.51. While the lowest estimate of $13 indicates a 11.6% decline from the current price leve ...

CVRx, Inc. (NASDAQ:CVRX) Q4 2024 Earnings Conference Call February 4, 2025 4:30 PM ET Company Participants Mike Vallie - Investor Relations, ICR Healthcare Kevin Hykes - President & Chief Executive Officer Jared Oasheim - Chief Financial Officer Conference Call Participants Rohin Patel - JPMorgan Macauley Kilbane - William Blair William Plovanic - Canaccord Genuity Samantha Munoz - Piper Sandler Frank Takkinen - Lake Street Capital Market Chase Knickerbocker - Craig-Hallum Capital Group Operator Greetings, ...

CVRx, Inc. (NASDAQ:CVRX) Q4 2024 Earnings Conference Call February 4, 2025 4:30 PM ET Company Participants Mike Vallie - Investor Relations, ICR Healthcare Kevin Hykes - President & Chief Executive Officer Jared Oasheim - Chief Financial Officer Conference Call Participants Rohin Patel - JPMorgan Macauley Kilbane - William Blair William Plovanic - Canaccord Genuity Samantha Munoz - Piper Sandler Frank Takkinen - Lake Street Capital Market Chase Knickerbocker - Craig-Hallum Capital Group Operator Greetings, ...

CVRx, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 13, 2025 (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation) (Commission File Number) Delaware 001-40545 41-1983744 (I.R.S. Employer Identification No.) 9201 West Broadway Avenue, Suite 650 Minneapolis, MN 55445 (Address of pr ...